Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Top Cited Papers
Open Access
- 4 September 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 388 (10056), 2115-2127
- https://doi.org/10.1016/s0140-6736(16)31324-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Risk factors for death in patients with severe asthmaJornal Brasileiro de Pneumologia, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Global asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health, 2012
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthmaJournal of Allergy and Clinical Immunology, 2010
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Economic burden of asthma: a systematic reviewBMC Pulmonary Medicine, 2009
- Tissue and BAL Based Biomarkers in AsthmaImmunology and Allergy Clinics of North America, 2007
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005